» Articles » PMID: 2409595

Rationale for Development of a Synthetic Vaccine Against Plasmodium Falciparum Malaria

Overview
Journal Science
Specialty Science
Date 1985 Jun 21
PMID 2409595
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.

Citing Articles

Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.

Yoo R, Jore M, Julien J Immunol Rev. 2025; 330(1):e70001.

PMID: 39907429 PMC: 11796336. DOI: 10.1111/imr.70001.


Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.

Wang L, Idris A, Kisalu N, Crompton P, Seder R Nat Immunol. 2024; 25(9):1530-1545.

PMID: 39198635 DOI: 10.1038/s41590-024-01938-2.


Vaccines and monoclonal antibodies: new tools for malaria control.

Miura K, Flores-Garcia Y, Long C, Zavala F Clin Microbiol Rev. 2024; 37(2):e0007123.

PMID: 38656211 PMC: 11237600. DOI: 10.1128/cmr.00071-23.


Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model.

Locke E, Flores-Garcia Y, Mayer B, MacGill R, Borate B, Salgado-Jimenez B NPJ Vaccines. 2024; 9(1):29.

PMID: 38341502 PMC: 10858969. DOI: 10.1038/s41541-024-00819-x.


Molecular determinants of cross-reactivity and potency by VH3-33 antibodies against the Plasmodium falciparum circumsporozoite protein.

Thai E, Murugan R, Binter S, Aschner C, Prieto K, Kassardjian A Cell Rep. 2023; 42(11):113330.

PMID: 38007690 PMC: 10720262. DOI: 10.1016/j.celrep.2023.113330.